- Conditions
- Lymphoma
- Interventions
- filgrastim, sargramostim, carboplatin, etoposide, ifosfamide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2003
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 821
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin's Lymphoma
- Interventions
- CD19CAR/virus specific T cells, Benadryl and Tylenol
- Genetic · Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2031
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mediastinal Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Gray-Zone Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Mediastinal Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
- Interventions
- Blinatumomab, Lenalidomide
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 17 more
- Conditions
- Lymphoma
- Interventions
- cryopreservation
- Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2011
- U.S. locations
- 82
- States / cities
- Anchorage, Alaska • Atlanta, Georgia • Austell, Georgia + 51 more
- Conditions
- Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell Leukemia/Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Interventions
- Cyclophosphamide, Fludarabine, Mogamulizumab, Natural Killer Cell Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Biological · Other
- Lead sponsor
- John Reneau
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Lymphoma
- Interventions
- apolizumab
- Biological
- Lead sponsor
- PDL BioPharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Freemont, California
- Conditions
- NHL, DLBCL, Non-hodgkin's Lymphoma, Diffuse Large B Cell Lymphoma
- Interventions
- AZD9150, Acalabrutinib, AZD6738, Hu5F9-G4, Rituximab, AZD5153
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Sarasota, Florida • Atlanta, Georgia + 7 more
- Conditions
- Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Non-Hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Tafasitamab, Tazemetostat, Zanubrutinib
- Procedure · Drug · Other + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 104
- States / cities
- Tucson, Arizona • Beverly Hills, California • Duarte, California + 81 more
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
- Interventions
- Mogamulizumab, Pembrolizumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 8
- States / cities
- Sacramento, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- Cancer
- Interventions
- ziv-aflibercept
- Biological
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Interventions
- Idelalisib, Rituximab, Bendamustine, Ofatumumab, Fludarabine, Everolimus, Bortezomib, Chlorambucil, Lenalidomide
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 11
- States / cities
- Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more
- Conditions
- Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 6
- States / cities
- Duarte, California • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Non-Hodgkins Lymphoma
- Interventions
- Lenalidomide
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Fountain Valley, California • Sacramento, California + 5 more
- Conditions
- Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Splenic Mantle Cell Lymphoma
- Interventions
- Akt/ERK Inhibitor ONC201, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
- Interventions
- PRT2527, Zanubrutinib, Venetoclax
- Drug
- Lead sponsor
- Prelude Therapeutics Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Duarte, California • Bethesda, Maryland • Boston, Massachusetts + 2 more
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Lenalidomide, Rituximab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 503 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 110
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 100 more
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- pixantrone, cyclophosphamide, vincristine, rituximab, prednisone, Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 9
- States / cities
- Fountain Valley, California • Los Angeles, California • Lakeland, Florida + 6 more
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Focal radiation therapy (RT)
- Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Lymphoma
- Interventions
- cisplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, syngeneic bone marrow transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Temple University
- Other
- Eligibility
- 15 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2000
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- temsirolimus
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 6
- States / cities
- Miami, Florida • East Orange, New Jersey • Oklahoma City, Oklahoma + 1 more
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma
- Interventions
- Buparlisib, Laboratory Biomarker Analysis, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- UCD19 CAR T Cells
- Biological
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Neoplasm Malignant
- Interventions
- SAR442257
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Duarte, California • Miami, Florida • Rochester, Minnesota
- Conditions
- Non-Hodgkins Lymphoma
- Interventions
- Velcade, Temsirolimus
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 18
- States / cities
- Rapid City, South Dakota • Green Bay, Wisconsin • La Crosse, Wisconsin + 11 more